Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$9.10 – $15.12
32% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.5M | $1.05B | $3.84B | $4.27B | $4.56B | $6.21B | $9.42B | $12.70B |
| Cost of revenue | −$1.3M | $124.9M | $387.8M | $573.0M | $931.0M | $1.81B | $1.51B | $1.71B |
| Gross profit | $10.8M | $922.6M | $3.46B | $3.70B | $3.63B | $4.40B | $7.91B | $10.99B |
| Gross margin | 113.8% | 88.1% | 89.9% | 86.6% | 79.6% | 70.9% | 84.0% | 86.5% |
| R&D | $1.22B | $1.29B | $1.85B | $2.48B | $2.87B | $2.23B | $2.68B | $2.56B |
| Operating income | −$1.79B | −$1.66B | −$557.2M | −$2.70B | −$3.12B | −$1.68B | −$755.9M | $1.97B |
| EBITDA | −$5.74B | −$1.57B | −$704.7M | −$2.37B | −$1.75B | −$660.7M | −$480.3M | $2.56B |
| Net income | −$5.77B | −$1.72B | −$998.4M | −$2.73B | −$2.18B | −$1.03B | −$94.6M | $792.6M |
| Net margin | -60900.0% | -164.2% | -26.0% | -63.9% | -47.8% | -16.6% | -1.0% | 6.2% |
| EPS (diluted) | -17.24 | -1.51 | -0.74 | -1.88 | -1.46 | -0.66 | -0.06 | 0.46 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19.0B | $1.43 | $1.15–$2.13 | 1 |
| 2027 | $22.8B | $2.29 | $1.85–$3.42 | 1 |
| 2028 | $27.0B | $3.10 | $2.49–$4.61 | 1 |
| 2029 | $33.9B | $4.46 | $3.59–$6.65 | 1 |
Forward consensus · source: Financial Modeling Prep
INNOVENT BIOLOGICS INC
No one on the platform currently holds IVBXF.
No tracked institution reports a position in IVBXF as of their last filing.
No one on the platform has traded IVBXF yet.
| $13.4B |
| — |
| GNMSFGenmab A/S | $275.00 | +10.00% | $16.9B | — |
| SBHMYSino Biopharmaceutical Limited | $12.68 | +0.00% | $11.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 1.5× sales vs its 1.3× historical median P/S.
Fair value ≈ $9.61 · price $11.03 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.